Modality
Multispecific
MOA
VEGFi
Target
CD20
Pathway
mTOR
PSPFTDALS
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Oct 2025
Phase 2Current
NCT04161833
2,617 pts·FTD
2021-01→TBD·Terminated
NCT05033149
824 pts·PSP
2023-08→2025-10·Completed
3,441 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-245mo agoPh2 Data· PSP
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2025-10-24 · 5mo ago
PSP
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04161833 | Phase 2 | FTD | Terminated | 2617 | Biomarker |
| NCT05033149 | Phase 2 | PSP | Completed | 824 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |